Is CTSO or ECOR more profitable?

electroCore has a net margin of -39.96% compared to Cytosorbents' net margin of -48.94%. Cytosorbents' return on equity of -431.65% beat electroCore's return on equity. Company Net Margins Return on Equity Return on Assets Cytosorbents -48.94% -431.65% -41.94% electroCore -39.96% -1,956.38% -81.35%

Is NRXS or CTSO more profitable?

Cytosorbents has a net margin of -48.94% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Cytosorbents' return on equity. Company Net Margins Return on Equity Return on Assets NeurAxis -492.76% N/A -641.25% Cytosorbents -48.94% -431.65% -41.94%

Is NNOX or CTSO more profitable?

Cytosorbents has a net margin of -48.94% compared to Nano-X Imaging's net margin of -716.44%. Nano-X Imaging's return on equity of -70.96% beat Cytosorbents' return on equity. Company Net Margins Return on Equity Return on Assets Nano-X Imaging -716.44% -70.96% -62.26% Cytosorbents -48.94% -431.65% -41.94%

Is CTSO or RNXT more profitable?

Cytosorbents has a net margin of -48.94% compared to RenovoRx's net margin of -621.71%. RenovoRx's return on equity of -135.11% beat Cytosorbents' return on equity. Company Net Margins Return on Equity Return on Assets Cytosorbents -48.94% -431.65% -41.94% RenovoRx -621.71% -135.11% -101.91%

Cytosorbents (CTSO) Competitors

$0.34 0.00 (-1.41%)

As of 08/28/2026 04:00 PM Eastern

Compare

CTSO vs. ECOR, OM, NRXS, NNOX, and RNXT

Should you buy Cytosorbents stock or one of its competitors? Cytosorbents's main competitors and comparable companies include electroCore (ECOR), Outset Medical (OM), NeurAxis (NRXS), Nano-X Imaging (NNOX), and RenovoRx (RNXT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Cytosorbents compare to electroCore?

Cytosorbents (NASDAQ:CTSO) and electroCore (NASDAQ:ECOR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Cytosorbents has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, electroCore has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

In the previous week, electroCore had 9 more articles in the media than Cytosorbents. MarketBeat recorded 10 mentions for electroCore and 1 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 0.94 beat electroCore's score of 0.66 indicating that Cytosorbents is being referred to more favorably in the media.

Company	Overall Sentiment
Cytosorbents	Positive
electroCore	Positive

Cytosorbents currently has a consensus price target of $5.38, suggesting a potential upside of 1,501.61%. electroCore has a consensus price target of $18.00, suggesting a potential upside of 86.92%. Given Cytosorbents' higher possible upside, equities analysts plainly believe Cytosorbents is more favorable than electroCore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cytosorbents has higher revenue and earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.57	-$8.20M	-$0.29	N/A
electroCore	$36.97M	2.35	-$13.97M	-$1.66	N/A

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 26.7% of electroCore shares are held by institutional investors. 7.8% of Cytosorbents shares are held by insiders. Comparatively, 7.8% of electroCore shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

electroCore has a net margin of -39.96% compared to Cytosorbents' net margin of -48.94%. Cytosorbents' return on equity of -431.65% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-48.94%	-431.65%	-41.94%
electroCore	-39.96%	-1,956.38%	-81.35%

Summary

Cytosorbents beats electroCore on 10 of the 13 factors compared between the two stocks.

How does Cytosorbents compare to Outset Medical?

Cytosorbents (NASDAQ:CTSO) and Outset Medical (NASDAQ:OM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Cytosorbents has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, Outset Medical has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market.

Cytosorbents has a net margin of -48.94% compared to Outset Medical's net margin of -63.06%. Outset Medical's return on equity of -61.67% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-48.94%	-431.65%	-41.94%
Outset Medical	-63.06%	-61.67%	-28.25%

Cytosorbents has higher earnings, but lower revenue than Outset Medical. Cytosorbents is trading at a lower price-to-earnings ratio than Outset Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.57	-$8.20M	-$0.29	N/A
Outset Medical	$117.80M	0.63	-$81.65M	-$4.09	N/A

Cytosorbents presently has a consensus target price of $5.38, suggesting a potential upside of 1,501.61%. Outset Medical has a consensus target price of $10.00, suggesting a potential upside of 153.81%. Given Cytosorbents' higher possible upside, equities research analysts clearly believe Cytosorbents is more favorable than Outset Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Outset Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

32.9% of Cytosorbents shares are held by institutional investors. 7.8% of Cytosorbents shares are held by insiders. Comparatively, 2.5% of Outset Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Outset Medical had 1 more articles in the media than Cytosorbents. MarketBeat recorded 2 mentions for Outset Medical and 1 mentions for Cytosorbents. Outset Medical's average media sentiment score of 1.32 beat Cytosorbents' score of 0.94 indicating that Outset Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Cytosorbents	Positive
Outset Medical	Positive

Summary

Outset Medical beats Cytosorbents on 10 of the 16 factors compared between the two stocks.

How does Cytosorbents compare to NeurAxis?

NeurAxis (NASDAQ:NRXS) and Cytosorbents (NASDAQ:CTSO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Cytosorbents has a net margin of -48.94% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
Cytosorbents	-48.94%	-431.65%	-41.94%

NeurAxis has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market.

Cytosorbents has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$5.32M	14.17	-$14.63M	-$0.78	N/A
Cytosorbents	$37.06M	0.57	-$8.20M	-$0.29	N/A

In the previous week, Cytosorbents had 1 more articles in the media than NeurAxis. MarketBeat recorded 1 mentions for Cytosorbents and 0 mentions for NeurAxis. Cytosorbents' average media sentiment score of 0.94 beat NeurAxis' score of 0.00 indicating that Cytosorbents is being referred to more favorably in the news media.

Company	Overall Sentiment
NeurAxis	Neutral
Cytosorbents	Positive

11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 32.9% of Cytosorbents shares are owned by institutional investors. 21.1% of NeurAxis shares are owned by insiders. Comparatively, 7.8% of Cytosorbents shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

NeurAxis presently has a consensus target price of $13.00, indicating a potential upside of 116.67%. Cytosorbents has a consensus target price of $5.38, indicating a potential upside of 1,501.61%. Given Cytosorbents' higher probable upside, analysts plainly believe Cytosorbents is more favorable than NeurAxis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cytosorbents beats NeurAxis on 10 of the 15 factors compared between the two stocks.

How does Cytosorbents compare to Nano-X Imaging?

Nano-X Imaging (NASDAQ:NNOX) and Cytosorbents (NASDAQ:CTSO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

In the previous week, Nano-X Imaging had 5 more articles in the media than Cytosorbents. MarketBeat recorded 6 mentions for Nano-X Imaging and 1 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 0.94 beat Nano-X Imaging's score of 0.48 indicating that Cytosorbents is being referred to more favorably in the news media.

Company	Overall Sentiment
Nano-X Imaging	Neutral
Cytosorbents	Positive

Cytosorbents has higher revenue and earnings than Nano-X Imaging. Cytosorbents is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nano-X Imaging	$14.52M	4.49	-$75.02M	-$1.58	N/A
Cytosorbents	$37.06M	0.57	-$8.20M	-$0.29	N/A

21.5% of Nano-X Imaging shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 7.7% of Nano-X Imaging shares are held by insiders. Comparatively, 7.8% of Cytosorbents shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cytosorbents has a net margin of -48.94% compared to Nano-X Imaging's net margin of -716.44%. Nano-X Imaging's return on equity of -70.96% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nano-X Imaging	-716.44%	-70.96%	-62.26%
Cytosorbents	-48.94%	-431.65%	-41.94%

Nano-X Imaging has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

Nano-X Imaging presently has a consensus target price of $4.33, indicating a potential upside of 422.34%. Cytosorbents has a consensus target price of $5.38, indicating a potential upside of 1,501.61%. Given Cytosorbents' higher possible upside, analysts clearly believe Cytosorbents is more favorable than Nano-X Imaging.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nano-X Imaging	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cytosorbents beats Nano-X Imaging on 10 of the 17 factors compared between the two stocks.

How does Cytosorbents compare to RenovoRx?

Cytosorbents (NASDAQ:CTSO) and RenovoRx (NASDAQ:RNXT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

In the previous week, RenovoRx had 4 more articles in the media than Cytosorbents. MarketBeat recorded 5 mentions for RenovoRx and 1 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 0.94 beat RenovoRx's score of 0.81 indicating that Cytosorbents is being referred to more favorably in the media.

Company	Overall Sentiment
Cytosorbents	Positive
RenovoRx	Positive

Cytosorbents has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, RenovoRx has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market.

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 3.1% of RenovoRx shares are owned by institutional investors. 7.8% of Cytosorbents shares are owned by company insiders. Comparatively, 9.4% of RenovoRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cytosorbents has higher revenue and earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.57	-$8.20M	-$0.29	N/A
RenovoRx	$1.12M	67.29	-$11.17M	-$0.31	N/A

Cytosorbents presently has a consensus price target of $5.38, indicating a potential upside of 1,501.61%. RenovoRx has a consensus price target of $8.50, indicating a potential upside of 408.98%. Given Cytosorbents' higher possible upside, equities analysts clearly believe Cytosorbents is more favorable than RenovoRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Cytosorbents has a net margin of -48.94% compared to RenovoRx's net margin of -621.71%. RenovoRx's return on equity of -135.11% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-48.94%	-431.65%	-41.94%
RenovoRx	-621.71%	-135.11%	-101.91%

Summary

Cytosorbents beats RenovoRx on 10 of the 17 factors compared between the two stocks.

Get Cytosorbents News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTSO vs. The Competition

Export

Metric	Cytosorbents	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$21.09M	$5.84B	$7.20B	$12.90B
Dividend Yield	N/A	1.75%	2.54%	11.28%
P/E Ratio	-1.16	25.92	273.16	25.45
Price / Sales	0.57	67.90	592.59	73.08
Price / Cash	N/A	33.03	76.74	53.00
Price / Book	-33.56	6.18	12.98	6.14
Net Income	-$8.20M	$149.01M	$3.48B	$348.86M
7 Day Performance	-9.30%	-0.24%	0.13%	-0.80%
1 Month Performance	-4.14%	6.18%	7.08%	4.13%
1 Year Performance	-64.43%	6.30%	24.67%	15.17%

Cytosorbents Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTSO Cytosorbents	2.2799 of 5 stars	$0.34 -1.4%	$5.38 +1,501.6%	-64.4%	$21.09M	$37.06M	N/A	220	Gap Down
ECOR electroCore	3.3224 of 5 stars	$9.47 -1.9%	$18.00 +90.1%	+81.4%	$85.42M	$32.03M	N/A	50	Positive News Insider Trade
OM Outset Medical	3.0334 of 5 stars	$4.30 +2.6%	$10.00 +132.6%	-71.7%	$80.84M	$119.48M	N/A	520	Positive News
NRXS NeurAxis	N/A	$6.04 -0.5%	$13.00 +115.2%	+136.2%	$75.85M	$5.32M	N/A	19
NNOX Nano-X Imaging	4.2584 of 5 stars	$0.86 -0.1%	$4.33 +402.1%	-78.6%	$67.82M	$13.02M	N/A	190	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTSO) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytosorbents (CTSO) Competitors

CTSO vs. ECOR, OM, NRXS, NNOX, and RNXT

How does Cytosorbents compare to electroCore?

Summary

How does Cytosorbents compare to Outset Medical?

Summary

How does Cytosorbents compare to NeurAxis?

Summary

How does Cytosorbents compare to Nano-X Imaging?

Summary

How does Cytosorbents compare to RenovoRx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTSO vs. The Competition

Cytosorbents Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytosorbents (CTSO) Competitors

CTSO vs. ECOR, OM, NRXS, NNOX, and RNXT

How does Cytosorbents compare to electroCore?

Which has more volatility & risk, CTSO or ECOR?

Does the media prefer CTSO or ECOR?

Do analysts rate CTSO or ECOR?

Which has stronger valuation and earnings, CTSO or ECOR?

Do insiders and institutionals hold more shares of CTSO or ECOR?

Is CTSO or ECOR more profitable?

Summary

How does Cytosorbents compare to Outset Medical?

Which has more risk and volatility, CTSO or OM?

Is CTSO or OM more profitable?

Which has better earnings & valuation, CTSO or OM?

Do analysts rate CTSO or OM?

Do institutionals & insiders hold more shares of CTSO or OM?

Does the media prefer CTSO or OM?

Summary

How does Cytosorbents compare to NeurAxis?

Is NRXS or CTSO more profitable?

Which has more risk & volatility, NRXS or CTSO?

Which has better valuation & earnings, NRXS or CTSO?

Does the media refer more to NRXS or CTSO?

Do institutionals and insiders have more ownership in NRXS or CTSO?

Do analysts rate NRXS or CTSO?

Summary

How does Cytosorbents compare to Nano-X Imaging?

Does the media refer more to NNOX or CTSO?

Which has higher valuation & earnings, NNOX or CTSO?

Do institutionals and insiders have more ownership in NNOX or CTSO?

Is NNOX or CTSO more profitable?

Which has more volatility & risk, NNOX or CTSO?

Do analysts prefer NNOX or CTSO?

Summary

How does Cytosorbents compare to RenovoRx?

Does the media prefer CTSO or RNXT?

Which has more volatility and risk, CTSO or RNXT?

Do insiders and institutionals believe in CTSO or RNXT?

Which has better valuation & earnings, CTSO or RNXT?

Do analysts prefer CTSO or RNXT?

Is CTSO or RNXT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTSO vs. The Competition

Cytosorbents Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools